BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Amendments to the Claims under Revised 37 C.F.R. § 1.121

Claim 1 (previously amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide is encoded by a nucleic acid molecule comprising the nucleotide sequence as set forth in any of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, residues 4 through 549 of SEQ ID NO: 9, residues 4 through 519 of SEQ ID NO: 15, or residues 4 through 516 of SEQ ID NO: 19.

Claim 2 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 9.

D2

Claim 3 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 15.

Claim 4 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 19.

Claim 5 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 5.

Claim 6 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 7.

Claim 7 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 13.

Claim 8 (previously amended): The method of Claim 1, wherein the nucleic acid molecule

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

comprises the nucleotide sequence as set forth in SEQ ID NO: 11.

Claim 9 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 17.

Claim 10 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 549 of the nucleotide sequence as set forth in SEQ ID NO: 9.

Claim 11 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 519 of the nucleotide sequence as set forth in SEQ ID NO: 15.

Claim 12 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 516 of the nucleotide sequence as set forth in SEQ ID NO: 19.

D2

Claim 13 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 3.

Claim 14 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1.

Claim 15 (previously amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide comprises the amino acid sequence as set forth in any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

NO: 16, or residues 2 through 172 of SEQ ID NO: 20; and

wherein said polypeptide has:

a) at least one conservative amino acid substitution;

b) at least one amino acid substitution at a glycosylation site;

c) at least one amino acid substitution at a proteolytic cleavage site;

d) at least one amino acid substitution at a cysteine residue;

e) at least one amino acid deletion;

f) at least one amino acid insertion;

g) a C- and/or N-terminal truncation; or

h) a combination of modifications selected from the group consisting of conservative amino acid substitutions, amino acid substitutions at a glycosylation site, amino acid substitutions at a proteolytic cleavage site, amino acid substitutions at a cysteine residue, amino acid deletions, amino acid insertions, C-terminal truncation, and N-terminal truncation.

D2

Claim 16 (previously amended) The method of Claim 15, wherein said encoded polypeptide has at least one conservative amino acid substitution.

Claim 17 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a glycosylation site.

Claim 18 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a proteolytic cleavage site.

Claim 19 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a cysteine residue.

Claim 20 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid deletion.

Claim 21 (previously amended) The method of Claim 15, wherein said encoded polypeptide

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

has at least one amino acid insertion.

Claim 22 (previously amended): The method of Claim 15, wherein said encoded polypeptide has a C- and/or N-terminal truncation.

Claim 23 (previously amended) A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide comprises the amino acid sequence as set forth in any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID NO: 16, or residues 2 through 172 of SEQ ID NO: 20.

D2

Claim 24 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 10.

Claim 25 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 16.

Claim 26 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 20.

Claim 27 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 6.

Claim 28 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 8.

Claim 29 (previously amended): The method of Claim 23, wherein said encoded polypeptide

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

comprises the amino acid sequence as set forth in SEQ ID NO: 14.

Claim 30 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 12.

Claim 31 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 18.

Claim 32 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 183 of the amino acid sequence as set forth in SEQ ID NO: 10.

Claim 33 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 173 of the amino acid sequence as set forth in SEQ ID NO: 16.

D2

Claim 34 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 172 of the amino acid sequence as set forth in SEQ ID NO: 20.

Claim 35 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 4.

Claim 36 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

Claim 37 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide comprises the amino

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

acid sequence of SEQ ID NO: 4 or a C- and/or N-terminally shortened sequence thereof.

Claim 38 (original): The method of Claim 37 wherein said polypeptide further comprises an amino-terminal methionine.

Claim 39 (original): The method of Claim 37, wherein said polypeptide comprises a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4.

Claim 40 (original): The method of Claim 39, wherein said polypeptide further comprises an amino-terminal methionine.

Claim 41 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4.

Claim 42 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Claim 43 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide consists of a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4.

Claim 44 (original): A method for ameliorating the harmful effects of TNF in an animal,

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide consists of a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Claim 45 (original): The method of either Claims 15 or 23, wherein said polypeptide has at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and the carboxyl-terminus.

Claim 46 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the amino-terminus.

Claim 47 (original): The method of Claim 46, wherein said polypeptide has a methionine at the amino-terminus.

Claim 48 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the carboxyl-terminus.

Claim 49 (currently amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide is encoded by a nucleic acid ~~which~~ that hybridizes ~~under moderately or highly stringent conditions~~ to the complement of the nucleic acid molecule ~~defined in~~ of Claim 1 at 65°C in a hybridization buffer comprising 6x SSC and 01.% SDS.

Claim 50 (original): The method of any of Claims 1, 15, or 23, wherein said polypeptide is chemically derivatized.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

Claim 51 (original): The method of any of Claims 1, 15, or 23, wherein said recombinant polypeptide is expressed in a cultured cell *in vitro* and said recombinant polypeptide is isolated therefrom.

Claim 52 (original): The method of Claim 51, wherein the cultured cell is a non-human cell.

Claim 53 (currently amended): The method of Claim 52, wherein the non-human cell ~~line~~ is a prokaryotic cell.

Claim 54 (original): The method of Claim 53, wherein the prokaryotic cell is *Escherichia coli*.

D2 Claim 55 (currently amended): The method of Claim 52, wherein the non-human cell ~~line~~ is a eukaryotic cell.

Claim 56 (original): The method of Claim 55, wherein the eukaryotic cell is a mammalian cell.

Claim 57 (original): The method of Claim 56, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claim 58 (original): The method of Claim 51, wherein the polypeptide is glycosylated.

Claim 59 (original): The method of Claim 51, wherein the polypeptide is not glycosylated.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001